Videos

Exploring How a Treatment Combo Improved Outcomes in Patients With AL Amyloidosis

07/08/2020

Raymond Comenzo, MD, hematologist, reviews the findings of the phase III ANDROMEDA trial and details how the addition of daratumumab improves hematologic responses and clinical outcomes.

Reference:

Kastritis E, Palladini G, Minnema MC, et al. Subcutaneous daratumumab + cyclophosphamide, bortezomib, and dexamethasone (cybord) in patients with newly diagnosed light chain (al) amyloidosis: primary results from the phase 3 andromeda study. EHA Library. 303396; Abstract: LB2604

What's Trending?

News

Expedient Postamputation Discharge Advised for Veterans Amid COVID-19 Pandemic

07/02/2020

“Until the pandemic is abated, telehealth should be utilized for routine follow-ups following amputation, and postoperative care should include screening for upper respiratory symptoms,” researchers advised.

“Until the pandemic is abated,...

07/02/2020

Veterans Health Today

News

715,200 Vials of Magnesium Sulfate Recalled

05/27/2016

The FDA announced the Class III recall of magnesium sulfate injection, USP 50%, 10 g/20 mL. The products were distributed by Hospira nationwide.

The FDA announced the Class III...

05/27/2016

Pharmacy Learning Network

News

State spending on Medicaid up sharply

12/06/2011

First Report Managed Care

News Connection

Integrated Delivery Systems for Hospital Inpatient Surgeries

10/23/2013

Jill Sederstorm ;

Integrated delivery systems (lDSs) have been shown to improve quality and lower costs in ambulatory care settings.

Integrated delivery systems...

10/23/2013

First Report Managed Care

News

Class II Recall of Lidocaine Initiated

03/10/2017

The FDA has initiated an active Class II recall for 7200 cartons of lidocaine cream.

Exploring How a Treatment Combo Improved Outcomes in Patients With AL Amyloidosis

What's Trending?

Stay Informed—Sign up today!

Specialties

Events

Year Round Education

HMP Global Products